482 related articles for article (PubMed ID: 21914348)
21. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
22. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
24. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
25. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
27. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
[TBL] [Abstract][Full Text] [Related]
28. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.
Guo CC; Zuo G; Cao D; Troncoso P; Czerniak BA
Mod Pathol; 2009 Jul; 22(7):866-71. PubMed ID: 19396154
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
[TBL] [Abstract][Full Text] [Related]
31. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
35. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
37. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.
Toubaji A; Albadine R; Meeker AK; Isaacs WB; Lotan T; Haffner MC; Chaux A; Epstein JI; Han M; Walsh PC; Partin AW; De Marzo AM; Platz EA; Netto GJ
Mod Pathol; 2011 Nov; 24(11):1511-20. PubMed ID: 21743434
[TBL] [Abstract][Full Text] [Related]
38. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
[TBL] [Abstract][Full Text] [Related]
40. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
